Member LoginDividend CushionValue Trap
|
Valuentum
Reports
Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for
any changes.
Latest
Valuentum Commentary
Mar 23, 2016
What Gilead’s Patent Miscue Means for Shareholders
Image Source: Gilead. Not much…right now, but we’re sleeping better at night not including shares in the newsletter portfolios. Feb 22, 2016
Key Treatment Momentum Drives Big Pharma
Let’s take a look at the recent results of some of the biggest names in Big Pharma. Feb 12, 2016
Your Hard-Earned Money
Valuentum is releasing its February Best Ideas Newsletter early, February 12, in light of Presidents’ Day weekend. Feb 2, 2016
Early Read: Gilead Guides Revenue to Decline in 2016, Below Consensus
The growth spurt may be over, and we’re most worried about the back half of this decade. Jan 29, 2016
Alerts: High-grading! GILD-->JNJ; EBAY-->FB
We’re “high-grading” the Best Ideas Newsletter portfolio. Nov 30, 2015
Dividend Increases/Decreases for the Week Ending November 27
Let's take a look at companies raising/lowering their dividends this week. Oct 28, 2015
Around the Horn in Biotech/Pharma: 3Q Earnings Review
Abbott, Biogen, Bristol-Myers, Eli Lilly, Gilead, GlaxoSmithKline, Merck, Pfizer… Oct 26, 2015
If It Happened to AbbVie, Could It Also Happen to Gilead?
Recent news concerning AbbVie’s hepatitis C drugs caused a severe decline in the company’s share price. Could such an event happen to Gilead? Oct 14, 2015
Video: Are Economic Moats Priced Into Stock Prices? -- You Bet They Are
President of Equity Research Brian Nelson debunks the myth that economic moats are not included in stock prices. Length: ~8 minutes. Aug 13, 2015
Big Pharma Earnings Continued…
Amgen, AstraZeneca, Merck, and Pfizer... Latest News and Media The High Yield Dividend Newsletter, Best Ideas
Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on
this website are for information purposes only and should not be considered a solicitation to buy or sell any
security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s
accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or
omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts
no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a
registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees,
and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.
|
|||||||||||||||||||||
